Atrial fibrillation (AF) is the most common arrhythmia worldwide and the majority of AF patients are treated in primary care. In order to minimize hospitalizations and visits to emergency departments, nurse-led care was introduced in secondary care and primary health care (PHC). However, even though nurse-led care was initiated in PHC almost a decade ago, and ESC guidelines recommended patient-centered integrated care including PHC for patients, there seems to be a lack of scientific evidence regarding the effects.

To review the scientific literature regarding the effects of nurse-led AF clinics in PHC.

A systematic review of scientific literature in Medline/Cinahl. Two reviewers independently assessed the retrieved articles.

Only one study was found that investigated the effectiveness of nurse-led structured AF management in PHC. The results from the study indicated positive effects; 45% reduction in all-cause mortality compared to usual care and significantly lower number of all-cause hospitalizations with nurse-led care. Several studies were found analyzing the effects of nurse-led AF-care in secondary care facilities, but only one in PHC setting. The results mainly showed that nurse-led care in AF-clinics in secondary care reduces mortality, hospitalizations and visits in emergency departments.

Even though only one study focused on PHC, the review indicated positive effects of nurse-led care for AF patients. However, the results are only based on studies performed in inpatient care. Hence, no firm conclusion can be drawn about nurse-led AF-clinics in PHC, and more research is clearly needed in this area.

PET imaging has become a valuable tool for assessing atherosclerosis by targeting key processes such as inflammation and microcalcification. Among available tracers, 18F-sodium fluoride has demonstrated superior performance compared to 18F-fluorodeoxyglucose, particularly in detecting coronary artery disease. However, the role of other tracers remains underexplored, requiring further validation. Emerging technologies such as artificial intelligence show potential in enhancing diagnostic speed and accuracy. Furthermore, the integration of the Alavi-Carlsen Calcification Score offers a novel approach to evaluating global disease burden, presenting a more clinically applicable method for predicting outcomes. Techniques such as total-body PET provide faster and more comprehensive imaging of the entire vascular system with reduced radiation exposure, representing a significant advancement in early detection and intervention. The combination of molecular imaging and advanced computational tools may revolutionize the management of atherosclerosis, facilitating earlier identification of at-risk individuals and improving long-term cardiovascular outcomes.

May Measurement Month (MMM) is a global campaign with the aim to improve awareness of arterial hypertension (AH). Kazakhstan participated in the campaign in 2021, 2022 and 2023.

During the cross-sectional 2021-2023 MMM surveys, volunteer adults (≥ 18 years) from cities in Kazakhstan had their blood pressure (BP) measured three times in a seated position, and received a questionnaire on their demographics, lifestyle and medical history. In those not receiving antihypertensive treatment, AH was defined as a mean systolic and/or diastolic BP ≥ 140/90 mmHg.

A total of 8231 individuals took part in the survey, with 1805 participants in 2021, 2410 participants in 2022 and 4016 participants in 2023. The prevalence of AH was estimated to be 37% in 2021 and 45% in 2022 and 2023. Of those identified as having AH, 51-70% were aware that they had the condition. Among those who were aware that they had AH, 68-91% were receiving antihypertensive therapy. However, 70-82% of treated participants were only receiving one to two drugs. BP was controlled to < 140/90 mmHg in 43-50% of treated participants and to < 130/80 mmHg in 15-16%.

The 2021, 2022 and 2023 MMM campaigns showed that high proportion of AH, a low level of AH awareness and inadequate BP control in Kazakhstan. Programs are needed to increase awareness of the risks of high BP and to improve the diagnosis and effective treatment of AH.

Non-alcoholic fatty liver disease (NAFLD) is strongly linked with metabolic syndrome and atherosclerotic cardiovascular diseases (ASCVDs). This study aimed to assess the feasibility of using brachial-ankle pulse wave velocity (baPWV), a non-invasive technique, to monitor atherosclerosis (AS) in NAFLD patients and to evaluate the AS risk in various sub-populations of NAFLD patients.

A cross-sectional study was conducted with 4,844 participants, enrolled from January 1, 2019, to December 31, 2021, at the Physical Examination Center of Zhongnan Hospital of Wuhan University. Participants were aged 18 to 88 years. According to the main points of the ultrasonic diagnosis of NAFLD, the ultrasonic image report was made for the subjects. AS is defined as baPWV ≥ 1,400 cm/s. We used multiple logistic regression analysis to explore the relationship between NAFLD and AS, and multiple linear regression analysis to explore the correlation between NAFLD and baPWV by modeling. Subgroup analysis was performed based on age and gender to adjust for confounding bias and complete sensitivity analysis.

The prevalence of NAFLD was 38.3% in all participants, with 45.4% in men and 25.1% in women. Among the overall NAFLD population and male NAFLD patients, baPWV exceeded the diagnostic threshold for AS (1,419.70 ± 205.51, 1,429.71 ± 196.13) starting from the 45-55 age group. Through the analysis of the age-baPWV scatter plots and fitted lines, along with sensitivity analysis, it is recommended that male patients should start monitoring at 46 years old for AS using baPWV, while female patients should begin at 51 years old. NAFLD was associated with increased odds of AS (OR: 1.206, 95% CI [1.021-1.423], P = 0.027) after adjusting for confounders. NAFLD was independently positively correlated with baPWV (Model 2: β = 0.086, ΔR 2 = 0.006, P < 0.001; Model 3: β = 0.05, P < 0.001). This positive correlation was also observed in both males and females (male: Model 2: β = 0.081, ΔR 2 = 0.005, P < 0.001; Model 3: β = 0.052, P = 0.001; female: Model 2: β = 0.088, ΔR 2 = 0.006, P < 0.001; Model 3: β = 0.042, P = 0.02).

NAFLD demonstrated an independent association with AS assessed via baPWV, an accessible non-invasive tool for early AS evaluation. Regular baPWV monitoring is recommended for NAFLD patients > 45 years, with males and females initiating surveillance at 46 and 51 years, respectively. Study limitations, including potential biases in NAFLD diagnosis, gender distribution imbalances, and confounding variable interdependencies, necessitate further stratified population analyses.

Large language model (LLM) offer promise in addressing layperson queries related to cardiovascular disease (CVD) prevention. However, the accuracy and consistency of information provided by current general LLMs remain unclear.

We evaluated capabilities of BARD (Google's bidirectional language model for semantic understanding), ChatGPT-3.5, ChatGPT-4.0 (OpenAI's conversational models for generating human-like text) and ERNIE (Baidu's knowledge-enhanced language model for context understanding) in addressing CVD prevention queries in English and Chinese. 75 CVD prevention questions were posed to each LLM. The primary outcome was the accuracy of responses (rated as appropriate, borderline, inappropriate).

For English prompts, the chatbots' appropriate ratings are as follows: BARD at 88.0%, ChatGPT-3.5 at 92.0%, and ChatGPT-4.0 at 97.3%. All models demonstrate temporal improvement in initially suboptimal responses, with BARD and ChatGPT-3.5 each improving by 67% (6/9 and 4/6), and ChatGPT-4.0 achieving a 100% (2/2) improvement rate. Both BARD and ChatGPT-4.0 outperform ChatGPT-3.5 in recognizing the correctness of their responses. For Chinese prompts, the "appropriate" ratings are: ERNIE at 84.0%, ChatGPT-3.5 at 88.0%, and ChatGPT-4.0 at 85.3%. However, ERNIE outperform ChatGPT-3.5 and ChatGPT-4.0 in temporal improvement and self-awareness of correctness.

For CVD prevention queries in English, ChatGPT-4.0 outperforms other LLMs in generating appropriate responses, temporal improvement, and self-awareness. The LLMs' performance drops slightly for Chinese queries, reflecting potential language bias in these LLMs. Given growing availability and accessibility of LLM chatbots, regular and rigorous evaluations are essential to thoroughly assess the quality and limitations of the medical information they provide across widely spoken languages.

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Low-density lipoprotein cholesterol (LDL-C) is a key therapeutic target, yet data on compliance with lipid goals in older adults from low- and middle-income countries are limited.

To evaluate the compliance with lipid profile goals in older adults.

This cross-sectional study analyzed 1270 adults aged ≥60 years from the Survey on Health, Well-being, and Ageing in Latin America and the Caribbean (SABE) Colombia 2015 survey. Cardiovascular risk was assessed via Framingham, ASCVD 2013, and SCORE2 models calibrated for Colombia, and lipid profile compliance was evaluated.

Most participants were at high or very high risk according to the SCORE2 (54.10%), ASCVD (10%), and Framingham (10.87%) criteria. LDL-C target compliance was low, ranging from 0.72% (Framingham) to 3.93% (ASCVD). Triglyceride targets were better achieved, with 54.88% meeting goals in the highest SCORE2 category.

Older Colombian adults have poor compliance with lipid goals, underscoring the urgent need for enhanced preventive strategies in this population.

Racial and ethnic disparities in hypertension care persist. Shared decision making (SDM) is promoted in hypertension guidelines. However, evidence is lacking on how race, ethnicity, and SDM relate, and the effect of SDM on hypertension control in diverse groups. We aimed to explore the relationships among SDM, blood pressure (BP), race and ethnicity, and other decision-making factors in patients with hypertension.

Longitudinal analysis of data from the RICH LIFE (Reducing Inequities in Care of Hypertension: Lifestyle Improvement for Everyone) project's participants (n=1426) with uncontrolled hypertension was performed using descriptive statistics, linear regression, and generalized estimating equations. Participants were middle-aged (mean age 60±11.6 years), predominantly women (59.4%, 847), non-Latino Black (59%, 844), and high school graduates or below (65%, 931). The mean SDM score was 7.2±2.6 out of 9, and the mean baseline systolic and diastolic BP were 152.2±12.0 and 85.3±12.1 mm Hg. Non-Latino Black people had 0.14 points higher mean SDM score (P<0.001) than non-Latino White people. Systolic BP reduction over 12 months was greater with a higher SDM mean score (β=-0.42, P=0.035). Baseline characteristics associated with SDM included more than high school education (β=-0.08, P=0.045), hypertension knowledge (β=-0.05, P=0.046), considering taking BP medication as very important (β=0.06, P=0.022), and patient activation (β=0.09, P=0.001).

There was greater BP reduction for patients with higher SDM score at follow-up, and associations between SDM and race and ethnicity, education, hypertension knowledge and attitude, and patient activation. Future research should further explore SDM differences among racial and ethnic groups to better align hypertension care with patients' needs.

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Comorbidities in patients with COPD significantly increase morbidity, mortality, and healthcare costs, posing a significant burden on the management of COPD. Given the complex clinical manifestations and varying severity of COPD comorbidities, accurate diagnosis and evaluation are particularly important in selecting appropriate treatment options. With the development of medical imaging technology, AI-based chest CT, as a noninvasive imaging modality, provides a detailed assessment of COPD comorbidities. Recent studies have shown that certain radiographic features on chest CT can be used as alternative markers of comorbidities in COPD patients. CT-based radiomics features provided incremental predictive value than clinical risk factors only, predicting an AUC of 0.73 for COPD combined with CVD. However, AI has inherent limitations such as lack of interpretability, and further research is needed to improve them. This review evaluates the progress of AI technology combined with chest CT imaging in COPD comorbidities, including lung cancer, cardiovascular disease, osteoporosis, sarcopenia, excess adipose depots, and pulmonary hypertension, with the aim of improving the understanding of imaging and the management of COPD comorbidities for the purpose of improving disease screening, efficacy assessment, and prognostic evaluation.

To evaluate the paths between lifelong physical activity levels and the development of cardiometabolic disease.

The ATTICA is a population-based cohort study with a 20-year follow-up conducted in the Attica region, Greece and included, 3042 adult males and females (45 [11] y). Participants physical activity levels' tracking together with data regarding cardiovascular disease, obesity, hypertension, hypercholesterolemia, and diabetes incidence, were available in 1988 participants (45 [12] y old, 987 males and 1001 females), at 20-year follow-up. Physical activity levels were evaluated using the validated International Physical Activity Questionnaire, in all examinations (2001-2002, 2006, 2012, and 2022). Four physical activity trajectories were defined, that is, consistently active/inactive and changed from active/inactive. Path analysis was applied using structure equation models.

54% of participants were classified as always inactive, 5% classified as became inactive from physically active, 38% as became active and, only 3% sustained physical activity levels. Participants who reported being consistently physically active throughout the 20-year period were 6% (OR, 0.94, 95% CI, 0.89-0.99) less likely to develop cardiovascular disease as compared with those who remained consistently physically inactive, had 21% lower risk of developing hypercholesterolemia (OR, 0.79, 95% CI, 0.59-1.04), 33% lower risk of obesity (OR, 0.67, 95% CI, 0.44-1.02), and 30% lower risk of diabetes (OR, 0.70, 95% CI, 0.48-1.03).

Lifelong physical activity was strongly associated with reduced fatal or nonfatal cardiovascular disease events, as well as reduced risk of developing other cardiometabolic disorders, hypercholesterolemia, obesity, and diabetes.

Inflammatory bowel disease (IBD) is a complex condition characterized by inflammation of the gastrointestinal system, encompassing Crohn's disease and ulcerative colitis. Patients diagnosed with IBD have an increased risk of atherosclerotic cardiovascular disease. This heightened risk can be attributed to a combination of mechanisms, including traditional risk factors, chronic inflammation, intestinal dysbiosis, increased risk of thrombosis, and the use of certain medications such as corticosteroids. There are significant gaps in current knowledge, particularly regarding the management of risk factors and the use of medications for cardiovascular disease prevention. Similarly, the cardiovascular effects of specific IBD therapies, particularly the newer ones, are not yet fully understood. This review focuses on the epidemiological evidence linking IBD with cardiovascular risk factors and cardiovascular disease. It describes the potential pathophysiological mechanisms underlying this association and examines the challenges involved in accurately assessing cardiovascular risk in these patients, including the utility of complementary tools such as subclinical atherosclerosis detection. Additionally, we consider the potential therapeutic implications for managing these patients. Finally, this review also underscores the importance of multidisciplinary collaboration. Effective teamwork among gastroenterologists, cardiologists, and general practitioners is essential for providing comprehensive care to patients with IBD.

Outcome benefits for HMG-CoA reductase inhibitor (statin) use in the prevention of atherosclerotic cardiovascular disease (ASCVD) are well established and yet, statins remain underutilized with only half of eligible individuals receiving them among certain vulnerable populations. This review critically examines available data to provide a summary of the current evidence for statin use in select populations.

Lipid management can be more complex in patients with chronic kidney disease (CKD), organ transplants, metabolic dysfunction associated with steatotic liver disease (MASLD), and human immunodeficiency virus (HIV). Statins are generally safe and effective to reduce the burden of ASCVD among these highly heterogeneous groups of patients and should be considered with careful attention to their concomitant disease state. Herein, we focus on appropriate statin use in these challenging to treat conditions, their relationship with increased ASCVD risk, and approaches to statin use for ASCVD risk reduction. Although further research is needed to define optimal therapy in select high risk groups for ASCVD prevention, statins are proven to be clinically efficacious, safe, and cost-effective for ASCVD prevention, warranting greater efforts to increase their use.

Atherosclerotic cardiovascular disease (ASCVD) remains a major cause of global morbidity and mortality. Emerging research suggests that oral hygiene practices, particularly dental floss use, may reduce the risk of ASCVD.

The purpose of this study was to examine the association between dental floss use and ASCVD prevalence.

Data from NHANES participants who completed home interviews and dental evaluations were analyzed. ASCVD was defined as angina, stroke, myocardial infarction, or coronary artery disease. Dental floss use was self-reported over the past seven days. Covariates included demographic, socioeconomic, lifestyle, and clinical factors. Weighted logistic regression was used to assess the relationship between dental floss use and ASCVD prevalence.

This study included a total sample of 7253 participants with a mean age of 53.8±14.6 years. The sample consisted of 47.6 % male participants. The ethnic composition included 64.3 % Non-Hispanic White. Regular dental floss use was correlated with a lower likelihood of developing ASCVD and Stringent Criteria (infarction or stroke), with ORs of 0.76 (95 % CI: 0.60, 0.97) p=0.028 and 0.68 (95 % CI: 0.49, 0.94) p=0.022, respectively. Flossing 3-4 days/week was associated with reduced ASCVD risk, OR = 0.57 (95 % CI: 0.38, 0.84) p=0.006. Similar reductions were seen for stringent criteria: flossing 3-4 days/week: OR = 0.57 (95 % CI: 0.32, 0.99) p=0.047, flossing ≥5 days/week: OR = 0.69 (95 % CI: 0.47, 1.00) p=0.049.

Regular dental floss use may reduce the risk of ASCVD. These results support the inclusion of oral hygiene practices in cardiovascular disease prevention strategies.

Currently, the joint and independent effects of intake of multiple dietary vitamins (including vitamin A, B1, B2, B6, B12, C, D, E, and K) on the prevalence of cardiovascular disease (CVD) in the chronic kidney disease (CKD) population are unclear, so this study was conducted to investigate mainly this point.

We collected National Health and Nutrition Examination Survey (NHANES) data from 2011 to 2016. We performed weighted multivariate logistic regression models to analyze the association of single dietary vitamins intake with CVD. Additionally, we examined the co-exposure of nine dietary vitamins, defined as their concurrent intake, and evaluated the potential additive or interactive effects of co-exposure of nine dietary vitamins on CVD risk in CKD patients using Bayesian kernel machine regression (BKMR) and weighted quantile sum (WQS) regression.

Finally, 2,203 CKD participants (weighted n = 27,120,429) were included, and 622 had CVD, with a CVD prevalence of 28.2%. In the fully adjusted model, by comparing the third tertile with the first tertile, the adjusted OR [T3 vs. T1] for the effect of vitamin B6 on CVD prevalence was 0.67 (95% CI, 0.51-0.89, p-value = 0.01), while that of vitamin E was 0.61 (95% CI, 0.42-0.87, p-value = 0.01). In the WQS model, the intake of nine dietary vitamins was negatively correlated with CVD prevalence (OR: 0.81, 95% CI: 0.70-0.93, p-value = 0.004). In the BKMR model, when the concentration was between the 25th and 75th percentiles, there was an overall negative correlation between the total intake of nine dietary vitamins and CVD prevalence.

High intakes of vitamin B6 and vitamin E were associated with low CVD risk in CKD patients, respectively. Additionally, nine dietary vitamins (vitamins A, B1, B2, B6, B12, C, D, E, and K) co-exposure were inversely correlated with the CVD prevalence in the CKD populations.

To provide a structured analysis of exercise interventions and outcome measures in older patients with frailty and heart failure (HF).

8 databases were searched up to May 22, 2024 to identify relevant studies. Two independent reviewers assessed and collected data according to the TIDieR checklist, CONTENT scale and COMET outcome taxonomy.

We screened 1,253 articles, resulting in 8 articles being included in the scoping review. Aerobic exercise and resistance training were fundamental elements of exercise rehabilitation, with balance training also being essential. Most exercise interventions are individualized, with the type and intensity of exercise being set and adjusted according to the patient's actual condition. However, the tailoring process of resistance training, including exercise load, sets, and repetitions, needs to be more detailed in most studies. The exercise interventions were provided by qualified therapists in most studies, and various methods were taken to ensure fidelity. None of the studies mentioned their theoretical basis. Only two exercise interventions were considered therapeutically valid. The two most commonly reported outcomes were physical function and quality of life.

It is necessary to focus on addressing research heterogeneity and report transparency to better implement exercise interventions in older frail adults with HF.

Delayed post-polypectomy bleeding (DPPB) is the most common adverse event following colonic polypectomy, yet its management remains highly heterogeneous and lacks standardization. A considerable number of colonoscopies performed for DPPB may be unnecessary and do not result in hemostatic intervention.

To develop evidence-based statements to guide clinical decision-making in DPPB.

Multidisciplinary Delphi consensus statement.

A panel of 29 experts in gastroenterology, hematology, radiology, and surgery was assembled. Through a systematic review of the literature and a modified Delphi process, consensus statements were developed through iterative rounds of anonymous voting. Statements were revised following anonymous voting and feedback at each round. Those achieving 80% agreement were accepted.

The expert panel reached a consensus on 36 statements, covering areas such as antithrombotic management, bowel preparation, colonoscopy indications, and therapeutic hemostatic modalities. Key recommendations include guidance for managing self-limited bleeding and risk stratification to reduce the rate of unnecessary colonoscopies, as well as recommendations for hemodynamically unstable patients who may require primary angioembolization. A practical clinical algorithm is proposed.

This document provides a consensus-based framework for managing DPPB. These recommendations aim to improve patient outcomes and optimize healthcare resources while fostering a standardized approach to this common adverse event.

Menopause is an important transition in a women's life that has been associated with a worsening cardiometabolic risk profile. Diabetes is a well-known risk factor for cardiovascular disease risk in women. Recent studies have improved the understanding of the hormonal and metabolic changes that occur during menopause, which have provided an opportunity to intervene with preventive efforts. Despite this, menopause's role and its direct (independent) relationship with cardiovascular risk factors, such as diabetes, remain largely unknown. This review highlights the inter-relationships between menopause, vasomotor symptoms, and menopausal hormone therapy with the risk of developing diabetes and outlines further knowledge gaps.

Data on congenital adrenal hyperplasia (CAH) disorders in the Saudi population are limited. This retrospective study assessed the clinical characteristics ofadolescents and adults with 21-hydroxylase CAH alongside the long-term outcomes of chronic glucocorticoid replacement therapy.

The study was conducted at the King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. The subjects included patients (aged ≥ 14 years) with 21-hydroxylase CAH, who attended the endocrine clinic between 2019 and 2021.

The study found that among the 108 patients with 21-hydroxylase deficiency considered, predominantly females (66.67%), with a median age of 21 years (IQR: 18-30), 93.51% had the classic salt-wasting form, while 6.49% had the nonsalt-wasting form. Glucocorticoid therapy for the patients included prednisone (46.3%), hydrocortisone (37.97%), and dexamethasone (12.03%). Short stature was observed in 30% of the patients, while obesity affected 35.19%. Among the females, 58.33% had oligomenorrhea. In addition, testicular adrenal rest tumors (TARTs) were detected in 44.44% of the males. Metabolic issues included high cholesterol in 95.65%, with 17.33% exhibiting prediabetics. Genetic testing identified CYP21A2 mutations in all patients tested.

short stature, obesity, and menstrual irregularities are highly prevalent in females, whereas TARTs are common in males. Although metabolic and bone health outcomes are generally favorable, the variability in hormonal control and its associated complications underscores the need for individualized glucocorticoid therapy. Continuous monitoring and improved treatment strategies are essential for optimizing the quality of life of patients with CAH.

Genome-wide association studies have revealed hundreds of genetic variants associated with cardiovascular diseases (CVD). Polygenic risk scores (PRS) can capture this information in a single metric and hold promise for use in CVD risk prediction. Importantly, PRS information can reflect the causally mediated risk to which the individual is exposed throughout life. Although European Society of Cardiology guidelines do not currently advocate their use in routine clinical practice, PRS are commercially available and increasingly sought by clinicians, health systems, and members of the public to inform personalized health care decision-making. This clinical consensus statement provides an overview of the scientific basis of PRS and evidence to date on their role in CVD risk prediction for the purposes of disease prevention. It provides the reader with a summary of the opportunities and challenges for implementation and identifies current gaps in supporting evidence. The document also lays out a potential roadmap by which the scientific and clinical community can navigate any future transition of PRS into routine clinical care. Finally, clinical scenarios are presented where information from PRS may hold most value and discuss organizational frameworks to enable responsible use of PRS testing while more evidence is being generated by clinical studies.

Statin medications play a pivotal role in the primary and secondary prevention and management of cardiovascular disease due to their potent lipid-lowering and anti-inflammatory effects. Nevertheless, the clinical application of statins is often hampered by statin-associated muscle symptoms (SAMS), which deter patient adherence and treatment efficacy considerably. SAMS currently affects 10-20% of statin users, thus understanding potential mitigation strategies is crucial. This review focuses on the role of vitamin D in mitigating SAMS, given the growing interest in vitamin D deficiency as a potentially modifiable risk factor.

Despite observational suggestions linking vitamin D deficiency to heightened SAMS risk, recent studies have yielded conflicting results on the role of vitamin D supplementation in preventing SAMS. Some studies report an improvement in statin tolerance following vitamin D repletion. However, recent large-scale clinical trials, particularly the Vitamin D and Omega-3 trial (VITAL) report no significant benefit of vitamin D supplementation in preventing SAMS or reducing statin discontinuation rates, regardless of baseline vitamin D levels.

Observational data provides evidence for the use of vitamin D supplementation in SAMS management, however conflicting evidence in recent clinical trials do not support its routine use for preventing or treating SAMS. To explore alternative strategies in improving statin tolerance and adherence, this discourse aims to elucidate the current understanding the complex mechanisms underlying SAMS, the influence of serum vitamin D levels, and the implications for clinical management.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as key agents for weight management, based on their marked efficacy as observed in randomized controlled trials. While still limited, real-world studies on GLP-1RA use in populations with obesity are increasingly available. This narrative review discusses contemporary real-world evidence demonstrating the utilization, clinical and comparative effectiveness, and adverse effects of the currently approved GLP-1RA-based weight-loss therapies, that is, liraglutide, semaglutide and tirzepatide. The observed weight reduction in clinical practice overall tends to be lower than in randomized controlled trials; however, outcomes approach those seen in trials when focusing on highly adherent patients. Real-world studies demonstrate high discontinuation rates of GLP-1RAs (20%-50%) within the first year, and the use of much lower doses than those evaluated in clinical trials. Evidence from observational studies within type 2 diabetes or obesity populations suggests frequent gastrointestinal disturbances in GLP-1RA users, as also observed in trials, but no clear increase in risks of severe events like pancreatitis or pancreatic cancer, thyroid disorders, or depression and self-harm. Further evidence is needed to understand possible real-world associations of GLP-1RAs with eye disease and other rare outcomes. We provide 10 areas of particular importance for further research on GLP-1RA within the real-world space, including improved understanding of the exact drivers of early discontinuation and suboptimal dosing, studies of the effects of stopping GLP-1RA treatment, and investigations of clinical and cost-effectiveness for hard clinical outcomes in real-world settings, including not only cardio-reno-metabolic outcomes but also obesity-induced diseases like neuropsychiatric disease, cancer, musculoskeletal disease, and infections. PLAIN LANGUAGE SUMMARY: Recent advancements in weight-loss medications have sparked a lot of interest. The so-called GLP-1 receptor agonist medications (GLP-1RAs) have gained a lot of attention, because they have shown to be very effective, leading to significant weight loss in patients participating in clinical trials. GLP-1RAs, like liraglutide, semaglutide, and tirzepatide, help manage weight by mimicking hormones that control blood sugar and appetite. However, how these medications perform in real life can be different from the controlled settings of clinical trials, in which patients are carefully selected and their treatment plans closely followed. This literature review looks at how these medications are used and their effectiveness and safety in real-world settings. In real-life practice, GLP-1RAs are often less effective than in clinical trial conditions. This is usually because patients don't follow their medication plans as strictly as in trials. Real-world data shows that many patients use lower doses and do not stick to their treatment as strictly as participants in a controlled trial might, leading to less weight loss. However, those who do follow their plans closely can achieve results similar to those in trials. A major issue with GLP-1RAs is that many patients stop using them within the first year due to side effects or high costs of the medications, especially if not covered by insurance. Common side effects include nausea and digestive problems, which are the main reasons patients stop taking these treatments. These side effects are often manageable and decrease over time, and this reviews found no strong real-world evidence that GLP-1RAs cause severe side effects in many users. Despite these challenges, when GLP-1RAs are used effectively and consistently, they show substantial benefits in weight loss, most so the newest medications semaglutide and tirzepatide. These medications are also likely to help manage and prevent weight-related health conditions like type 2 diabetes and cardiovascular disease, but evidence for these beneficial outcomes is still scarce in real-world settings. The review emphasizes the need for more research to understand why many patients stop using these medications and how to improve dosing. It also calls for studies on the long-term effects of these therapies on various health outcomes, including mental health, cardiometabolic health, cancer, and rare conditions like eye diseases. Overall, while GLP-1RAs are a valuable tool for weight management, their real-world use requires careful consideration of individual patient factors, such as the ability to stick to treatment plans, manage side effects, and afford the medications. Further research will help make these treatments more effective for a wider range of people that need them.

Socioeconomic status (SES) is one of key social determinants of health. Compared to individual-level SES, the association between area-level SES and hypertension management has been understudied and under-recognised. In this study, we aimed to assess the association between area-level SES and hypertension awareness, treatment, combination therapy and control, and the modification effect of individual characteristics on the associations.

During Dec 2015 and Dec 2022, 1,559,748 residents with hypertension aged 35-75 years from 31 provinces in the China Health Evaluation And risk Reduction through nationwide Teamwork (ChinaHEART) were included. The composite value of area-level SES was generated from national census data and categorized into tertiles. Multivariable mixed models with random effects to account for county-level administrative area were fitted to compute odds ratios (OR) and 95% confidence intervals (CIs) for the independent and interactive associations of both area- and individual-level SES with hypertension management (awareness, treatment, combination therapy and control) and their disparities across different population subgroups.

Among the included participants with hypertension aged 59·1 ± 9·1 years, 794,675 (50·95%), 650,485 (41·70%) and 206,103 (13·21%) were aware, treated, and controlled, respectively. Compared with the high area-level SES group, the low group was significantly associated with a lower odds of hypertension awareness (OR: 0·75, 95% CI: 0·65-0·86), treatment (0·69, 0·59-0·81), combination therapy (0·65, 0·51-0·84), and control (0·62, 0·51-0·75). Participants with low SES at both individual and area level had the lowest odds of hypertension management. Area-level SES had stronger influences on hypertension awareness, treatment and control, but a weaker influence on combination therapy, in the young and those with high individual-level SES.

Area-level SES on plays a key role in the awareness, treatment, combination therapy and control of hypertension, with different magnitude of associations. Integrated action to improve area-level circumstances and promote targeted interventions to hypertension care cascade are needed to reduce health inequalities in China.

The CAMS Innovation Fund for Medical Science; the National High Level Hospital Clinical Research Funding; the National Natural Science Foundation of China of China; the Ministry of Finance of China and National Health Commission of China; the 111 Project from the Ministry of Education of China.

Elevated low-density lipoprotein-cholesterol (LDL-C) is a modifiable risk factor for dementia, but evidence on other lipids is inconsistent, particularly in studies from low and middle-income countries. This study aimed to assess the association between lipid levels and cognitive decline in the ELSA-Brasil cohort.

In this prospective study, baseline serum lipid profile [total cholesterol (TC), LDL-C, high-density lipoprotein-cholesterol (HDL-C), triglycerides, and non-high-density lipoprotein-cholesterol (Non-HDL-C)] was analyzed. Cognition was assessed in three waves four years apart using the CERAD Word List, the semantic and phonemic verbal fluency, Trail Making Test B (TMT-B), and a global score.

ln 12,870 individuals at baseline, the mean (SD) age was 51.4 (8.9) years old, 55.4 % were women, and 53.4 % White. Over eight years of follow-up, inverted U-shape associations of TC with memory [Effective Degrees of Freedom (EDF) = 2.975; P = 0.006] and global cognitive decline (EDF = 2.957; P = 0.014), LDL-C with memory (EDF = 2.976; P = 0.021), verbal fluency (EDF = 2.973; P = 0.041), and global cognitive decline (EDF = 2.962; P = 0.030), and Non-HDL-C with memory (EDF = 2.975; P = 0.012) and global cognitive decline (EDF = 2.963; P = 0.035) were observed. A cubic-shaped association with TMT-B (EDF = 2.981; P = 0.005) was observed for HDL-C. Inverted U-shape associations of TC (EDF = 2.946; P < 0.001), LDL-C (EDF = 2.956; P = 0.007), and Non-HDL-C (EDF = 2.951; P = 0.006) in participants aged less than 60 years and inverted U-shape associations of TC (EDF = 2.882; P = 0.044) in women were observed for global cognitive decline.

Non-linear associations of baseline serum lipids with a decline in different cognitive domains over eight years of follow-up were observed, particularly in individuals younger than 60 years and in women.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent liver condition. We investigated whether statin use reduces liver-related events (LREs) risk among patients with MASLD or MASLD with increased alcohol intake (MetALD).

This nationwide cohort study included individuals aged ≥40 years with MASLD/MetALD undergoing health examinations between 2012 and 2013. The primary outcome was LREs; hepatocellular carcinoma (HCC), decompensated liver cirrhosis (DLC), and liver-related mortality. Secondary outcomes included HCC, DLC, and steatotic liver disease (SLD) regression, all-cause mortality, cardiovascular diseases (CVD)-related mortality, and liver-related mortality, respectively. Multivariable Cox regression was performed to estimate the risk of LREs associated with statin use.

Among 516,575 individuals (median follow-up: 10.1 years), statin users experienced significantly lower LRE rates (1.6%) compared with non-users (2.0%, p <0.001). Multivariable Cox regression analysis revealed that statin use was associated with reduced risks of LREs (adjusted hazard ratio [aHR] 0.64, 95% CI 0.61-0.68), HCC (aHR 0.52, 95% CI 0.47-0.58), DLC (aHR 0.58, 95% CI 0.52-0.65), all-cause mortality (aHR 0.81, 95% CI 0.78-0.84), CVD-related mortality (aHR 0.87, 95% CI 0.80-0.95), and liver-related mortality (aHR 0.51, 95% CI 0.46-0.57). Furthermore, statin use was associated with SLD regression (aHR 1.18, 95% CI 1.15-1.21). Stratified analyses consistently demonstrated risk reductions across all subgroups, particularly in patients with elevated alanine aminotransferase levels. Sensitivity analyses confirmed the robustness of these associations.

Statins are significantly associated with reduced LRE risk in patients with MASLD, especially among those with elevated alanine aminotransferase levels, suggesting a viable preventive strategy for such population.

Our study provides critical evidence supporting the role of statins in reducing liver-related events in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), a condition with significant global health impact. These findings are particularly relevant for clinicians managing high-risk patients with MASLD, especially those with elevated alanine aminotransferase levels, as they highlight the potential for statins to mitigate both liver and cardiovascular risks. By demonstrating the robustness of these results through comprehensive sensitivity and stratified analyses, our research underscores the importance of integrating statin therapy into the management of MASLD. This has practical implications for physicians, researchers, and policymakers in developing guidelines and preventive strategies to improve long-term liver and cardiovascular outcomes.

Atherosclerotic cardiovascular disease remains a major cause of death, and it is important to accurately estimate the cardiovascular events risk stratification even in asymptomatic patients. The coronary artery calcium score (CACS), which is quantitatively evaluated by electrocardiogram (ECG)-gated non-contrast chest computed tomography (CT) imaging, has been reported to be useful for cardiovascular event risk stratification in large studies. In the USA and Europe, guidelines recommend the use of the CACS in borderline or intermediate-risk asymptomatic individuals based on a high level of evidence. In Japan, however, the use of CACS in clinical practice is currently limited. Although it has been reported that the prevalence and distribution of coronary artery calcification (CAC) may differ by race and ethnicity, there are few data on its usefulness in stratifying the risk of cardiovascular events in asymptomatic Japanese individuals. While it is important to establish evidence for the usefulness of CACS in the Japanese population, for widespread clinical dissemination it would be beneficial to evaluate CAC and to perform accurate cardiovascular event risk stratification from non-ECG-gated non-contrast chest CT imaging performed during medical check-up and routine clinical practice. There have been reports on the usefulness of CAC assessed by non-ECG-gated chest CT imaging and on the relationship of CAC between ECG-gated and non-ECG-gated chest CT imaging. In recent years, a more accurate method of evaluating CACS from non-ECG-gated chest CT imaging has been developed using artificial intelligence, and further development is expected in the future.

Despite an increasingly diverse population, knowledge regarding racial and ethnic disparities is limited among women and men undergoing atherosclerotic cardiovascular (ASCVD) risk assessment.

The aim of this study was to compare cardiovascular (CV) mortality by ASCVD risk and coronary artery calcium (CAC) scores among Black and Hispanic women and men compared with other participants.

From the CAC Consortium, 42,964 participants with self-reported race and ethnicity were followed for a median of 11.7 years. Multivariable Cox proportional hazards regression models were used to estimate CV mortality, with separate analyses by sex.

One-third of enrollees were women; 977 self-reported as Black, 1,349 as Hispanic, 1,621 as Asian, and 740 as American Indian/Native Alaskan/Hawaiian or unspecified; the remainder were White. Black women and men had higher ASCVD risk and CAC scores yielding the highest CV mortality compared with other participants. Among Black women and men with a 0 CAC or ASCVD risk score <5%, HRs were 6- to 9-fold higher than that of other women and men. In men with CAC scores ≥100, Black men (HR: 4.2; P < 0.001) had the highest CV mortality compared to all other men. A similar high-risk pattern was noted for Black women with CAC scores ≥100 (P < 0.001), even with adjustment for the ASCVD risk score. Overall, Hispanics had an intermediate CV mortality, less than that of Black participants. This was notable for Hispanic men with a CAC score of 0 (HR: 3.6; P = 0.006) and CAC ≥100 (HR: 2.3; P = 0.03).

The disproportionately high and excess CV mortality among Black women and men represents significant barriers to reducing the burden of ASCVD through effective risk assessment using ASCVD risk and CAC scores.

Depression, anxiety, distress and Type D personality traits have been implicated in the pathogenesis of cardiovascular diseases. Mental health status is associated with arrhythmic events. Esler and Lampert reported that anxiety and distress contribute to the occurrence of atrial and ventricular arrhythmias. ■ Self-reported cardiac symptoms not associated with arrhythmias. ■ High prevalence of anxiety and depression symptoms. ■ Anxiety was correlated with self-reported cardiac symptoms.

This study aimed to examine the presence of psychological characteristics and their association with self-reported cardiac symptoms in individuals undergoing 24-hour Holter monitoring.

This observational cross-sectional study included 304 individuals who consecutively underwent 24-hour Holter monitoring. Clinical, demographic, and electrocardiographic data were collected. Psycho-behavioral characteristics were assessed using the Hospital Anxiety and Depression Scale and the Type D Scale. Logistic regression models were employed to examine associations between cardiac symptoms and anxiety, depression, distress, and Type D personality traits. Statistical significance was set at p<0.05.

Anxiety, depression, distress, and type D personality traits were observed in 42.7%, 15.1%, 26.3%, and 19% of the participants, respectively. Logistic regression analysis revealed a significant association between the perception of cardiac symptoms and both mild anxiety (odds ratio (OR) = 2.305, 95%CI= 1.098-4.841, p=0.027) and severe anxiety (OR = 9.245, 95%CI= 1.582-54.013, p=0.014) scores. No significant association was found between depression, distress, or Type D personality traits and an increased perception of cardiac symptoms.

A high prevalence of anxiety was observed among individuals undergoing 24-hour Holter recording. Anxiety was significantly associated with self-reported cardiac symptoms, though not with the presence of arrhythmias. The findings could have practical implications for clinical practice. The study suggests that patients reporting anxious palpitations should receive a more thorough cardiological assessment, with 24-hour Holter monitoring serving as an effective tool for this evaluation.

Chronic inflammation, via multiple pathways, influences blood pressure and lipid profiles, serving as a significant risk factor for the onset of cardiovascular disease (CVD). Anti-inflammatory dietary patterns may ameliorate CVD risk factors through the modulation of inflammatory mediators and metabolic factors, potentially leading to improved cardiovascular outcomes. Current findings regarding the relationship between dietary habits and CVD risk factors, such as blood pressure and lipid levels, exhibit considerable variability. We performed a comprehensive systematic review and meta-analysis to explore the possible association between anti-inflammatory dietary patterns (such as the Mediterranean diet, DASH diet, Nordic diet, Ketogenic diet, and Vegetarian diet) and CVD risk factors.

We conducted a comprehensive search across five databases: PubMed, Web of Science, Cochrane Library, Embase, and China National Knowledge Infrastructure (CNKI). Ultimately, we identified 18 eligible randomized controlled trials (including randomized crossover trials), which were subjected to meta-analysis utilizing RevMan 5 and Stata 18.

A comprehensive meta-analysis of these studies conducted based on random effects model indicated that, in comparison to an Omnivorous diet, interventions centered on anti-inflammatory diets were linked to significant reductions in Systolic Blood Pressure (SBP) (MD: -3.99, 95% CI: -6.01 to -1.97; p = 0.0001), Diastolic Blood Pressure (DBP) (MD: -1.81, 95% CI: -2.73 to -0.88; p = 0.0001), Low Density Lipoprotein Cholesterol (LDL-C) (SMD: -0.23, 95% CI: -0.39 to -0.07; p = 0.004), Total Cholesterol (TC) (SMD: -0.31, 95% CI: -0.43 to -0.18; p < 0.00001) and High-sensitivity C-reactive Protein (hs-CRP) (SMD: -0.16, 95% CI: -0.31 to -0.00; p = 0.04). No notable correlations were identified between High Density Lipoprotein Cholesterol (HDL-C) and Triglycerides (TG).

The findings indicate that anti-inflammatory diets may lower serum hs-CRP levels and positively influence the reduction of CVD risk factors, such as blood pressure and lipid profiles, thereby contributing to the prevention and progression of cardiovascular conditions. Most of the outcome indicators had low heterogeneity; sensitivity analyses were subsequently conducted on outcome measures demonstrating substantial heterogeneity, revealing that the findings remained consistent.

Recent studies have highlighted the association between polycystic ovary syndrome (PCOS) and cardiometabolic diseases, leading to an improved understanding of the underlying mechanistic factors. PCOS significantly increases cardiovascular risk by predisposing individuals to various subclinical and clinical conditions, including atherosclerosis and type 2 diabetes mellitus. Additionally, it interacts synergistically with other traditional cardiovascular risk factors, such as obesity, hyperlipidemia, and insulin resistance. Several molecular mechanisms involving genetics, epigenetics, adipokine secretion, hyperandrogenemia, and hyperinsulinemia play a role in the relationship between PCOS and these comorbidities. For instance, androgen excess has been implicated in the development of hypertension, type 2 diabetes mellitus, endothelial dysfunction, and ultimately, broader cardiovascular disease. A deeper understanding of these underlying mechanisms facilitates the development of diagnostic, preventative, and therapeutic strategies directed at reducing cardiometabolic morbidity. This narrative review summarizes the current evidence, explores the potential clinical implications of these findings, and discusses emerging therapies to reduce cardiometabolic morbidity in women with PCOS.

The Asian American (AA) population is the fastest-growing major racial group in the U.S. Typically treated as a monolith in research, disaggregated data show disproportionate cardiovascular disease (CVD) burden among certain AA ethnic groups. This analysis aimed to identify which factors explain variance in cardiovascular health among AA ethnic groups. We analyzed pooled 2010-2018 National Health Interview Survey data from Chinese, Asian Indian, Filipino, and Other Asian adults in the U.S. CVD outcomes of interest were coronary heart disease, heart attack, and stroke. Covariates included sociodemographic characteristics, CVD-related health conditions, and behaviors. Variance explained by sociodemographic, health behaviors, and health conditions were calculated based on the adjusted R-squared from a series of five models for each CVD health outcome. Of the 10,353 AA adults in the sample, 53% identified as female. Compared to the aggregate AA sample and the other ethnic groups, Filipinos had a higher burden of any CVD outcome (5.9%), particularly for coronary heart disease (4.0%). The combination of all predictors explained at most 13% of variance, with sociodemographic characteristics accounting for at least half of the variance explained among all participants. Health behaviors explained a greater amount of additional variance for all CVD outcomes among Asian Indians, including an additional 3.1% for stroke. Inversely, existing health conditions were significant predictors of CVD for all AA ethnic groups compared to Asian Indians. There is heterogeneity in CVD outcomes and related risk factors in AA ethnic groups, emphasizing the need for culturally tailored prevention and intervention strategies.

Elevated lipoprotein(a) [Lp(a)], high-sensitivity C-Reactive Protein (hs-CRP), and total homocysteine (tHcy) are associated with atherosclerotic cardiovascular disease (ASCVD) risk. This study investigated the individual and joint associations of Lp(a), hs-CRP and tHcy with coronary heart disease (CHD) and stroke.

This study was conducted in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort (2000-2017) (CHD analytic N = 6,676; stroke analytic N = 6,674 men and women). Associations between Lp(a) (<50 vs. ≥50 mg/dL), hs-CRP (<2 vs. ≥2 mg/L) and tHcy (<12 vs. ≥12 µmol/L) and CHD and stroke incidence were evaluated individually and jointly using Cox proportional hazards regression.

Individually, elevated tHcy was associated with CHD and stroke incidence, Lp(a) with CHD only and hs-CRP with stroke only. In combined analyses, CHD risk was higher when multiple biomarkers were elevated [hs-CRP+Lp(a), hazard ratio (HR)=1.39, 95 % confidence interval (CI): 1.06, 1.82; hs-CRP+ tHcy, HR = 1.34, 95 % CI: 1.02, 1.75; Lp(a)+ tHcy HR = 1.58, 95 % CI: 1.08, 2.30; hs-CRP+Lp(a)+ tHcy HR = 2.02, 95 % CI: 1.26, 3.24]. Stroke risk was elevated when hs-CRP and either Lp(a) (HR = 1.51, 95 % CI: 1.02, 2.23) or tHcy (HR = 2.10, 95 % CI: 1.44, 3.06) was also high, when all three biomarkers were elevated (HR = 2.99, 95 % CI: 1.61, 5.58), or when hs-CRP and tHcy (HR = 1.79, 95 % CI: 1.16, 2.76) were both high.

Risk of ASCVD was highest with concomitant elevation of tHcy, hs-CRP and Lp(a). Inclusion of tHcy and consideration of biomarker combination rather than individual biomarker levels may help better identify individuals at greatest risk for ASCVD events.

The objective of this study was to assess differences in dietary behavior and clinical risk factor outcomes and explore predictors of change among patients participating in traditional and Pritikin intensive cardiac rehabilitation (CR).

This secondary analysis of cardiac registry data from 2015 to 2021 included patients participating in traditional CR (n = 420) or Pritikin intensive CR (n = 1005) at a single hospital site. Dietary behavior outcomes included the Rate Your Plate measure, while clinical risk factor outcomes included fasting lipids, blood pressure, anthropometrics, functional outcomes, and psychosocial assessment. Analysis of covariance examined a difference in Rate Your Plate scores between CR groups. Multivariate analysis of covariance was used to determine differences in clinical risk factor variables between CR groups. Predictors of change in dietary behavior and clinical risk factors were determined through multiple bivariate linear regression models within each CR group.

Both CR programs led to significant improvements though more change was observed among Pritikin intensive CR participants in dietary behavior, anthropometrics, and fasting lipids. Status as a current or recent smoker was not a significant predictor of dietary behavior. Male sex, status as a current or recent smoker, beta-blockers, and angiotensin-converting enzyme inhibitors prescribed were not significant predictors of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or non-high-density lipoprotein cholesterol for traditional and Pritikin intensive CR groups. There were not significant predictors of blood pressure, body mass, or waist circumference.

Although participation in either CR program yielded cardiometabolic benefits, Pritikin intensive CR patients exhibited significantly greater improvements in dietary behavior and clinical risk factors.

Yixin Tongmai Granules (YTG) is a popular Chinese herbal granules for the treatment of coronary artery disease (CAD), but its molecular pharmacological mechanism is still unclear. This article explores the mechanism of CAD treatment from the perspective of network pharmacology. We analyzed the chemical composition of YTG using UHPLC-MS/MS and identified 131 ingredients. The relative drug content of 33 ingredients exceeded 0.5%. These ingredients were further screened using the SwissADME platform with ADME criteria. Using the HIT database and SwissTargetPrediction platform, high probability targets for these ingredients were generated. Using Venn Diagram, 96 effective targets associated with CAD were identified, involving 14 core ingredients. This study imported these effective targets into the STRING platform and obtained the core targets through network topology analysis: TP53, STAT3, transcription factor Jun, MAPK3, MAPK1, AKT1, SRC, MYC, BCL2, transcription factor p65, TNF, and ESR2. Then enrichment analysis with Metascape platform indicated that, in the system network of YTG in anti-CAD, the principal pathways are "Lipid and Atherosclerosis", "Pathways in cancer", and "AGE-RAGE signaling pathway in diabetic complications." Next, the affinities between the core ingredients and their associated core targets were examined individually through molecular docking. Finally, based on deep mining of PubMed literature, this study investigated the relationship between each core target and CAD, the relationship between each core target and its associated core ingredients, and inferred the main pharmacological ingredients of YTG, namely Tanshinone IIA, Cryptotanshinone, Caffeic acid, Denshensu, Ononin, and Formononetin.

Premature coronary artery disease (CAD) is defined by the early onset of significant atherosclerotic narrowing of the coronary arteries, generally occurring before age 55 in men and 60 in women. This condition is an increasing concern in cardiovascular medicine due to its impact on younger populations, resulting in greater morbidity, diminished quality of life, and a substantial economic burden. Common risk factors include dyslipidemia, hypertension, diabetes, smoking, obesity, and genetic predispositions such as familial hyperlipidemia. This case report describes a 19-year-old male with no known cardiovascular risk factors who presented with an ST-segment elevation myocardial infarction and ventricular tachycardia caused by left main coronary artery disease including the left anterior descending artery and the left circumflex artery. Despite lacking common risk factors, he underwent successful coronary artery bypass grafting with two grafts.

Patient and public involvement and engagement (PPIE) has gained global recognition as an innovative healthcare research practice. PPIE engages end-users throughout the research process, improving intervention effectiveness, resource efficiency, and user satisfaction. Despite its increasing inclusion in studies, comprehensive bibliometric reviews of healthcare intervention-related studies reporting PPIE are scarce. This study aims to conduct a bibliometric analysis of healthcare intervention-related studies reporting PPIE in recent decades to identify key worldwide bibliometric features, themes, and trends.

The analysis includes 10,624 relevant English articles published in the Web of Science (WoS) Core Collection up to 26 November 2024. Search terms were selected based on PPIE conceptualization, interventional types, and related healthcare terms. Using WoS descriptive analysis and CiteSpace, we examined bibliometric features and identified major international themes and trends.

There has been a significant increase in the number of healthcare intervention-related studies reporting PPIE over the past five years, especially from the United States and the United Kingdom, with a recent rise in Asia. However, cross-national collaboration remains limited. Key research themes identified include "community participation", "health equity", "coronary heart disease", "web-based patient empowerment", "mental illness", and "obesity prevention", with growing interest in "mobile health" and "digital health".

This study provides a comprehensive and up-to-date overview of the bibliometric characteristics and evolving trends in healthcare intervention-related studies reporting PPIE. It highlights global regions with limited PPIE implementation, suggests pathways for further development, and identifies key research themes. The study offers researchers and practitioners valuable insights into tracking PPIE trends in healthcare interventions and fostering collaborations on evidence-based PPIE studies with leading scholars and institutions worldwide. Additionally, the findings drive innovations aimed at improving patient and public healthcare outcomes.